J. Geller

发表

Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group.

C. Roehrborn, M. Resnick, S. Kaplan, 1999, Urology.

Overview of benign prostatic hypertrophy.

J. Geller, 1989, Urology.

Surgical orthotopic implantation allows high lung and lymph node metastatic expression of human prostate carcinoma cell line PC‐3 in nude mice

Xiaoen Wang, A. Moossa, R. Hoffman, 1998, The Prostate.

The Bisphosphonate Olpadronate Inhibits Skeletal Prostate Cancer Progression in a Green Fluorescent Protein Nude Mouse Model

Meng Yang, R. Hoffman, L. Deftos, 2006, Clinical Cancer Research.

Recombinant methioninase infusion reduces the biochemical endpoint of serum methionine with minimal toxicity in high-stage cancer patients.

R. Hoffman, Y. Tan, M. Xu, 1997, Anticancer research.

Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen.

J. Geller, 1990, The Journal of clinical endocrinology and metabolism.

Benign Prostatic Hyperplasia: Pathogenesis and Medical Therapy

J. Geller, 1991, Journal of the American Geriatrics Society.

Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia.

J. Wilson, Jean D. Wilson, E. Stoner, 1992, The Journal of clinical endocrinology and metabolism.

Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study Group.

J. Trachtenberg, M. Elhilali, P. Narayan, 1999, Urology.

The effect of finasteride in men with benign prostatic hyperplasia. 1992.

G. Andriole, P. Walsh, E. Vaughan, 2002, The Journal of urology.

Acute effects of testicular and adrenal cortical blockade on protein synthesis and dihydrotestosterone content of human prostate tissue.

J. Geller, J. Liu, J. Albert, 1985, The Journal of clinical endocrinology and metabolism.

The effectiveness of reducing the daily dose of finasteride in men with benign prostatic hyperplasia

M. Sullivan, J. Geller, 2002, BMC urology.

Panel IX: Alternatives to surgery for benign prostatic hyperplasia

H. Lepor, L. Denis, J. Mcconnell, 1992 .

HUMAN BENIGN PROSTATIC HYPERPLASIA.

J. Geller, K. Nakao, P. Mao, 1965, Archives of pathology.

An orthotopic mouse model of remetastasis of human colon cancer liver metastasis.

R. Gamagami, R. Hoffman, A. Moossa, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Dihydrotestosterone concentration in prostate cancer tissue as a predictor of tumor differentiation and hormonal dependency.

J. Geller, J. Albert, D. J. de la Vega, 1978, Cancer research.

Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy.

J. Geller, J. Albert, D. Loza, 1984, The Journal of urology.

Review of assessment of total androgen blockade as treatment of metastatic prostate cancer

J. Geller, 1991, Journal of endocrinological investigation.

Effect of megestrol acetate on uroflow rates in patients with benign prostatic hypertrophy: double-blind study.

C. Pratt, J. Geller, J. Albert, 1979, Urology.

Inadequate Adrenergic Response to Disopyramide-Induced Hypoglycemia

J. Geller, Michael Sullivan, R. C. Smith, 1992, The Annals of pharmacotherapy.

Medical castration of males with megestrol acetate and small doses of diethylstilbestrol.

S. Yen, J. Geller, J. Albert, 1981, The Journal of clinical endocrinology and metabolism.

Hemodynamic Studies in a Case of Carcinoid Cardiovascular Syndrome

P. Kohn, J. Geller, B. Charms, 1959, Circulation.

Comparison of androgen metabolites in benign prostatic hypertrophy (BPH) and normal prostate.

G. Niwayama, J. Geller, J. Albert, 1976, The Journal of clinical endocrinology and metabolism.

DHT concentrations in human prostate cancer tissue.

J. Geller, J. Albert, D. J. de la Vega, 1978, The Journal of clinical endocrinology and metabolism.

Steroid levels in cancer of the prostate--markers of tumour differentiation and adequacy of anti-androgen therapy.

J. Geller, J. Albert, D. Loza, 1979, Journal of steroid biochemistry.

Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia.

M. Lieber, M. Elhilali, G. Andriole, 2003, Urology.

The Long-Term Effect Of Specific Type II 5α-Reductase Inhibition With Finasteride on Bone Mineral Density in Men: Results of a 4-Year Placebo Controlled Trial

D. Kadmon, J. Waldstreicher, M. McClung, 2002 .

The Clinical Effects of a 5α-Reductase Inhibitor, Finasteride, on Benign Prostatic Hyperplasia

E. Vaughan, E. Stein, J. Imperato-McGinley, 1992 .

Effect of megestrol acetate (Megace) on steroid metabolism and steroid-protein binding in the human prostate.

S. Yen, J. Geller, T. Cantor, 1976, The Journal of clinical endocrinology and metabolism.

Monitoring of skeletal progression of prostate cancer by GFP imaging, X‐ray, and serum OPG and PTHrP

P. Jiang, R. Hoffman, M. Yang, 2005, The Prostate.

Adrenal androgen blockade in relapsed prostate cancer.

J. Geller, J. Albert, 1985, European journal of cancer & clinical oncology.

Castration‐like effects on the human prostate of a 5α‐reductase inhibitor, finasteride

J. Geller, L. Sionit, 1992 .

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.

R C Bruskewitz, G. Andriole, P. Walsh, 2002, The New England journal of medicine.

Clinical review: 67: Approach to chemoprevention of prostate cancer.

J. Geller, 1995, The Journal of clinical endocrinology and metabolism.

The long-term effect of specific type II 5alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial.

D. Kadmon, J. Waldstreicher, M. McClung, 2002, The Journal of urology.

Comparison of dihydrotestosterone levels in prostatic cancer metastases and primary prostate cancer

J. Geller, C. D. Candari, Cesar D. Candari, 1989, The Prostate.

High‐malignancy orthotopic nude mouse model of human prostate cancer LNCaP

Xiaoen Wang, R. Hoffman, Z. An, 1999, The Prostate.

The effects of flutamide on total DHT and nuclear DHT levels in the human prostate

J. Geller, J. Albert, D. Loza, 1981, The Prostate.

Treatment of advanced cancer of prostate with megestrol acetate.

S. Yen, J. Geller, J. Albert, 1978, Urology.

Basis for hormonal management of advanced prostate cancer

J. Geller, 1993, Cancer.

Overview of enzyme inhibitors and anti-androgens in prostatic cancer.

J. Geller, Jack Geller, 1991, Journal of andrology.

Proscar: five-year experience.

J. Imperato-McGinley, W. Bremner, D. Vaughan, 1995, European urology.

A method for tissue extraction and determination of prostate concentrations of endogenous androgens by radioimmunoassay.

J. Geller, J. Albert, D. Lopez, 1976, Journal of immunological methods.

Effect of tamoxifen on stromal protein synthesis in the human prostate.

L. E. Faber, J. Geller, J. Liu, 1984, The Journal of clinical endocrinology and metabolism.

Rationale for blockade of adrenal as well as testicular androgens in the treatment of advanced prostate cancer.

J. Geller, 1985, Seminars in oncology.

New sensitive discovery histoculture model for growth‐inhibition studies in prostate cancer and BPH

R. Hoffman, J. Geller, G. Olbina, 1998, The Prostate.

Advantages of total androgen blockade in the treatment of advanced prostate cancer.

J. Geller, A. Vik, J. Albert, 1988, Seminars in oncology.

The Case for Total Androgen Blockade in the Management of Metastatic Prostate Cancer

J. Geller, J. Albert, 1988 .

Endocrine therapy: predictors of response to prostatic cancer.

J. Geller, J. Albert, 1983, Seminars in urology.

RELATIONSHIP BETWEEN HUMAN PROSTATIC EPITHELIAL CELL PROTEIN SYNTHESIS AND TISSUE DIHYDROTESTOSTERONE LEVEL

W. Fay, J. Geller, J. Liu, 1987, Clinical endocrinology.

Evidence for a specific dihydrotestosterone-binding cytosol receptor in the human prostate.

J. Geller, T. Cantor, J. Albert, 1975, The Journal of clinical endocrinology and metabolism.

Medical treatlllent of benign prostatic hypertrophy

J. Geller, 1974 .

Medical treatment of benign prostatic hypertrophy

J. Geller, 1974 .

Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer

Meng Yang, R. Hoffman, S. Penman, 2007, Proceedings of the National Academy of Sciences.

The role of adrenal steroids on renal function and electrolyte metabolism.

J. Geller, J. Gabrilove, L. Soffer, 1957, Bulletin of the New York Academy of Medicine.

Real‐time whole‐body imaging of an orthotopic metastatic prostate cancer model expressing red fluorescent protein

Meng Yang, P. Jiang, N. Yamamoto, 2005, The Prostate.

Prostate concentrations of endogenous androgens by radioimmunoassay.

J. Geller, J. Albert, D. Lopez, 1976, Journal of steroid biochemistry.

The effect of cyproterone acetate on advanced carcinoma of the prostate.

J. Geller, K. Nakao, H. Newman, 1968, Surgery, gynecology & obstetrics.

Expression of prostate-specific antigen in human prostate specimens in in vitro three-dimensional histoculture

R. Hoffman, J. Geller, K. Connors, 1993, In Vitro Cellular & Developmental Biology - Animal.

Comparison of androgen‐independent growth and androgen‐dependent growth in BPH and cancer tissue from the same radical prostatectomies in sponge‐gel matrix histoculture

J. Geller, R. Hoffman, Yuying Tan, 1997, The Prostate.

Genistein inhibits the growth of human‐patient BPH and prostate cancer in histoculture

R. Hoffman, Lingna Li, J. Geller, 1998, The Prostate.

Measurement of androgen sensitivity in the human prostate in in vitro three‐dimensional histoculture

R. Hoffman, J. Geller, K. Connors, 1992, The Prostate.

Effect of cyproterone acetate on 3H-testosterone uptake and enzyme synthesis by the ventral prostate of the rat.

E. Seifter, O. Van Damme, J. Geller, 1969, Endocrinology.

The Effect of Progestational Agents on Male Gonadal and Pituitary Function.

J. Geller, A. Loh, A. Baron, 1969 .

Effect of progestational agents on gonadal and adrenal cortical function in patients with benign prostatic hypertrophy and carcinoma of the prostate.

J. Geller, H. Newman, B. Fruchtman, 1967, The Journal of clinical endocrinology and metabolism.

An improved method for extraction and determination of prostate concentrations of endogenous androgens.

J. Geller, J. Albert, D. Loza, 1978, Journal of steroid biochemistry.

Inhibin in the human prostate.

A. Sheth, J. Geller, J. Albert, 1981, Archives of andrology.

Prophylactic noscapine therapy inhibits human prostate cancer progression and metastasis in a mouse model.

M. Rogosnitzky, J. Geller, I. Barken, 2010, Anticancer research.

Noscapine inhibits human prostate cancer progression and metastasis in a mouse model.

M. Rogosnitzky, J. Geller, I. Barken, 2008, Anticancer research.

DHT in prostate cancer tissue— a guide to management and therapy

J. Geller, J. Albert, 1985, The Prostate.

Tamoxifen decreases progesterone and nuclear androgen receptors in the human prostate.

L. E. Faber, J. Geller, J Geller, 1984, Journal of steroid biochemistry.

Tissue dihydrotestosterone levels and clinical response to hormonal therapy in patients with advanced prostate cancer.

J. Geller, J. Albert, D. J. de la Vega, 1984, The Journal of clinical endocrinology and metabolism.

Objective remission of metastatic breast carcinoma in a male who recieved 17-alpha hydroxy progesterone caproate (delalutin).

H. Volk, J. Geller, M. Lewin, 1961, Cancer chemotherapy reports.

Controversies : Endocrine therapy of prostate cancer : optimal form and appropriate timing

E. Crawford, F. Labrie, J. Geller, 1995 .

Response of the plasma 17-hydroxycorticosteroid level to gel-ACTH in tumorous and non-tumorous Cushing's syndrome.

J. Geller, J. Gabrilove, L. Soffer, 1957, The Journal of clinical endocrinology and metabolism.

Effect of prednisone on adrenal responsiveness to corticotropin in normal subjects and in patients with treated and untreated Cushing's syndrome.

J. Geller, J. Gabrilove, A. DE FREITAS, 1958, The Journal of clinical endocrinology and metabolism.

Response of plasma 17, 21-dihydroxy-20-ketosteroids to repository corticotropin.

J. Geller, J. Gabrilove, L. Soffer, 1957, The Journal of clinical endocrinology and metabolism.

Direct evidence that PTHrP expression promotes prostate cancer progression in bone.

Robert M Hoffman, R. Hoffman, L. Deftos, 2005, Biochemical and biophysical research communications.

TREATMENT OF BENIGN PROSTATIC HYPERTROPHY WITH HYDROXYPROGESTERONE CAPROATE: EFFECT ON CLINICAL SYMPTOMS, MORPHOLOGY, AND ENDOCRINE FUNCTION.

J. Geller, R. Bora, H. Newman, 1965, JAMA.

Therapy with progestational agents in advanced benign prostatic hypertrophy.

A. Angrist, J. Geller, K. Nakao, 1969, JAMA.

Oxandrolone effect on growth and bone age in idiopathic growth failure.

J. Geller, 1968, Acta endocrinologica.

THE EFFECT OF 17-ALPHA-ETHYL-19-NORTESTOSTERONE AND 17-ALPHA-ETHYL-19-NORTESTERONE 3-ENOL-PROPIONATE ON GROWTH AND ENDOCRINE FUNCTION IN NORMAL YOUNG MALES OF SHORT STATURE.

J. Geller, 1964, Acta endocrinologica.

Muscular dystrophy: evaluation of adrenal cortical function and influence of corticotropin, cortisone and testosterone.

J. Geller, J. Gabrilove, L. Soffer, 1958, Metabolism: clinical and experimental.

Effect of progestational agents on carcinoma of the prostate.

J. Geller, H. Newman, B. Fruchtman, 1967, Cancer chemotherapy reports.

Pathogenesis and medical treatment of benign prostatic hyperplasia

J. Geller, J Geller, 1989, The Prostate. Supplement.

Therapeutic controversies: clinical treatment of benign prostatic hyperplasia.

H. Lepor, J. Geller, A. Levine, 1995, The Journal of clinical endocrinology and metabolism.

Five-year follow-up of patients with benign prostatic hyperplasia treated with finasteride.

J. Geller, 1995, European urology.

Megestrol acetate plus low-dose estrogen in the management of advanced prostatic carcinoma.

J. Geller, 1991, The Urologic clinics of North America.

Effect of antiandrogen and/or antiestrogen blockade on human prostate epithelial and stromal cell protein synthesis.

C. Berry, W. Fay, J. Geller, 1986, Journal of steroid biochemistry.

Effects of androgen blockade with ketoconazole and megestrol acetate on human prostatic protein patterns

J. Geller, J. Albert, Junda Liu, 1986, The Prostate.

Effects of castration compared with total androgen blockade on tissue dihydrotestosterone (DHT) concentration in benign prostatic hyperplasia (BPH)

J. Geller, J. Albert, 1987, Urological Research.

Comparison of various hormonal therapies for prostatic carcinoma.

J. Geller, J. Albert, 1983, Seminars in oncology.

Medical castration with megestrol acetate and minidose of diethylstilbestrol.

S. Yen, S S Yen, J. Geller, 1981, Urology.

Castration-like effects on the human prostate of a 5 alpha-reductase inhibitor, finasteride.

J. Geller, L. Sionit, 1992, Journal of cellular biochemistry. Supplement.

Effect of Cholesterol Atherosclerosis, Hypertension and Cortisone on Aortic Oxygen Consumption in Rabbit

E. Fisher, J. Geller, 1960, Circulation research.

The type of current frequency used in transurethral resection of prostate (TURP) affects the androgen receptor

J. Geller, J. Albert, D. Nachtsheim, 1982, The Prostate.

Triple chromosomal mosaicism XY-XXY-XXxY in Klinefelter's syndrome.

J. Geller, L. Y. Hsu, I. Nemhauser, 1966, The Journal of clinical endocrinology and metabolism.

Effect of 17-ethyl-19-nortestosterone 3-enol propionate (SC-7294) on the metabolism of adrenal cortical steroids.

J. Geller, 1962, The Journal of clinical endocrinology and metabolism.

Comment on prostatic hyperplasia in patients with acromegaly.

J. Geller, 1998, Journal of Clinical Endocrinology and Metabolism.

Steroid levels in cancer of the prostate--markers of tumor differentiation and adequacy of anti-androgen therapy.

S. Lippman, J. Geller, J. Albert, 1979, Progress in clinical and biological research.

The effect of finasteride in men with benign prostatic hyperplasia.

G. Andriole, P. Walsh, J. Imperato-McGinley, 1992, The Journal of urology.

Prolonging survival in metastatic prostate cancer: the case for adrenal androgens--overview and summary of therapeutic controversies in prostatic cancer.

J. Geller, 1995, Journal of Clinical Endocrinology and Metabolism.

IDENTIFICATION AND MEASUREMENT OF GROWTH HORMONE IN EXTRACTS OF HUMAN URINE.

J. Geller, Arthur Loh, 1963, The Journal of clinical endocrinology and metabolism.

In vivo and in vitro effects of androgen on fibroblast growth factor‐2 concentrations in the human prostate

R. Hoffman, A. Baird, J. Geller, 1994, The Prostate.

Acute therapy with megestrol acetate decreases nuclear and cytosol androgen receptors in human BPH tissue

J. Geller, J. Albert, S. Geller, 1982, The Prostate.

Effect of cyproterone acetate on clinical, endocrine and pathological features of benign prostatic hypertrophy.

J. Geller, T. Cantor, J. Fishman, 1975, Journal of steroid biochemistry.

Effects of heat and pH on radioimmunoassay and activity of prostatic acid phosphatase compared.

J. Geller, J. Albert, 1980, Clinical chemistry.